Lupus Management: Monitoring and Treating to Minimize Organ Damage and Optimize Outcomes
Jointly provided by
This educational activity is supported by an educational grant from GlaxoSmithKline.
Release date: 7/15/2022
Expiration date: 7/15/2023
Estimated time to complete: 1.0 hour
Management of systemic lupus erythematosus (SLE) is complicated by its variable and often subtle presentation, yet prompt diagnosis and treatment is essential to preventing organ damage and its consequent morbidity and mortality. Hydroxychloroquine and glucocorticoids are options for achieving SLE control, though long-term use of the latter is associated with dose-related damage. Fortunately, newer targeted agents are providing clinicians with options for minimizing glucocorticoid use. Additionally, disease activity monitoring has proven valuable in minimizing flares and limiting organ damage.
This activity uses two virtual patient cases to review current recommendations for SLE management, including the use of new targeted therapies and strategies for monitoring disease activity, adjusting treatment when necessary, and optimizing patient outcomes.
Joan T. Merrill, MD—Program Chair
Director of Clinical Projects, Arthritis & Clinical Immunology Program
Oklahoma Medical Research Foundation (OMRF)
OMRF Professor of Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Anca D. Askanase, MD, MPH
Professor of Medicine, Division of Rheumatology
Columbia University College of Physicians & Surgeons
Director, Columbia University Lupus Center
New York, New York
Michelle A. Petri, MD, MPH
Professor of Medicine
Johns Hopkins University School of Medicine
This activity has been designed to meet the educational needs of rheumatologists and other health care providers (HCPs) who are involved in the care of patients with SLE.
Upon completion of this activity, participants should be better able to:
- Monitor disease activity to promptly recognize exacerbations (flares)
- Employ regular monitoring to maximize disease control, minimize medication side effects, prevent SLE-related organ damage, inform clinical decision-making, and adjust therapy as needed
- Apply the most current safety and efficacy data when using new and emerging targeted SLE therapies
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RedMedEd. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes completion of the evaluation, enables the participant to earn up to 1.0 Maintenance of Certification (MOC) points in the American Board of Internal Medicine’s (ABIM) MOC program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Anca D. Askanase, MD, MPH, has disclosed the following relevant financial relationships:
Grant/Research Support: Eli Lily, Pfizer, Idorsia, UCB
Consultant/Advisory Board: AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, Celgene, Janssen, Genentech, GlaxoSmithKline, Mallinckrodt
Joan T. Merrill, MD, has disclosed the following relevant financial relationships:
Grant/Research Support: AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline
Consulant: AbbVie, Alexion, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, EMD Serono, Gilead, Genentech, GlaxoSmithKline, Lilly, Merck, Pfizer, Provention, Remegen, Sanofi, UCB, Zenas
Michelle A. Petri, MD, MPH, has disclosed the following relevant financial relationships:
Grant/Research Support: AstraZeneca, Eli Lilly, Exagen, GlaxoSmithKline, Janssen, Thermofisher
Consultant/Advisory Board: Alexion, Amgen, AstraZeneca, Axdev, Boston Pharmaceuticals, Emergent Biosolutions, Gilead Biosciences, GlaxoSmithKline, IQVIA, Idorsia Pharmaceuticals, Janssen, Kezar Life Sciences, Lilly, Merck EMD Serono, Momenta Pharmaceuticals, PPD Development, Sanofi, UCB
Postgraduate Institute for Medicine
The Postgraduate Institute for Medicine planners and others have nothing to disclose.
The RedMedEd planners have disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact the Postgraduate Institute for Medicine at firstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or email@example.com.
- iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection
- Internet browsers: Chrome, Firefox, Safari
- A computer with an Internet connection
- Internet browsers (PC): Chrome, Firefox, Microsoft Edge
- Internet browsers (Mac): Chrome, Firefox, Safari
© 2022. This CME/CE-certified program is held as copyrighted by the Postgraduate Institute for Medicine and RedMedEd. Through this notice, the Postgraduate Institute for Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.